{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008560","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.677768+00:00","generated_at":"2026-06-15T11:51:50.348389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tactile Medical Q1 revenue up 23% to $58.8M; raises FY2023 guidance to $271-275M","bullets":["Q1 revenue $58.8M (+23% YoY); net loss narrowed to $1.9M ($0.09 diluted) from $15.6M loss ($0.78).","Lymphedema revenue +22%, airway clearance +24%; gross margin 70.5%.","Adjusted EBITDA turned positive to $0.5M from ($2.6M) loss in Q1 2022.","FY2023 revenue guidance raised to $271-275M (prior $269-273M), growth ~10-11.5%.","Closed public equity offering raising $34.6M net; appointed Elaine Birkemeyer as CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008560","json":"https://secwatch.observer/filing/0001558370-23-008560.json","markdown":"https://secwatch.observer/filing/0001558370-23-008560.md","text":"https://secwatch.observer/filing/0001558370-23-008560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023008560/0001558370-23-008560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023008560/tcmd-20230508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:51:50.348389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a65217ddee9112fee350823388aae4eda57a8f9e","claim":"TACTILE SYSTEMS TECHNOLOGY INC reported first quarter ended March 31, 2023 results: revenue $58.8 million, net income Net loss of $1.9 million, or $0.09 per diluted share, EPS $0.09 per diluted share. Guidance raised.","evidence_excerpt":"with chronic disorders , today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary: ● Total revenue increased 23% year-over-year to $58.8 million ● Lymphedema products revenue increased 22% year-over-year ● Airway clearance products revenue increased 24% year-over-year ● Operating loss of $3.8 million versus $14.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1027838/000155837023008560/0001558370-23-008560-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$58.8 million"},{"label":"Net income","value":"Net loss of $1.9 million, or $0.09 per diluted share"},{"label":"EPS","value":"$0.09 per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}